ArticleHeliyon2025
Genetic variations and clinical significance in young-onset nasopharyngeal cancer: Analysis of EBV interaction with cellular receptor variants and viral glycoproteins.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal cancer (NPC), although rare in young individuals worldwide, is significantly influenced by the Epstein-Barr virus (EBV). Considering EBV's widespread prevalence, understanding its role in NPC's future occurrence, disease progression, clinical symptoms, metastatic tendencies, and prognosis is crucial. In this study, we extensively analyzed two young patients with NPC, who displayed distinct clinical features. We utilized Whole Exome Sequencing (WES), concentrating on EBV-interacting receptors, and applied advanced in silico methods for a deeper investigation. These methods included structural analysis via SWISS-MODEL, stability assessments using PremPS, and molecular docking studies with ClusPro. Our focus was to analyze genetic variants identified by WES and confirm EBV presence using RT-qPCR. Our comparative study between the two subjects showed that the first had milder symptoms and a lower metastasis than the second. In the first subject, we identified unique genetic variants: NRP1 c.536T > C (p.Val179Ala) and MYH9 c.4876A > G (p.Ile1626Val). Notably, the NRP1 p.Val179Ala variant caused structural changes leading to protein instability. Molecular docking suggested that this variant enhances interaction more than the wild-type. RT-qPCR validation of EBV showed lower levels in subject one (mutant-NRP1) compared to subject two (wild-type-NRP1). This finding implies that the p.Val179Ala variant in subject one could obstruct EBV entry, possibly leading to less severe clinical symptoms Our research provides new insights into the genetic factors influencing the clinical presentation of NPC, identifying promising targets for further research and therapeutic interventions. However, additional validation in a larger cohort is required to elucidate the broader impact of these genetic variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.